Trial · NCT03013491
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
NCT03013491, Phase 1, Phase 2, Terminated, CytomX Therapeutics; results first posted 2025-06-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas. Trials, record NCT03013491. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03013491
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- NCT number
- NCT03013491
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 196 participants, actual
- Lead sponsor
- CytomX Therapeutics
- Conditions
- Solid Tumor, Lymphoma
- Interventions
- CX-072, ipilimumab, vemurafenib
- First posted
- 2017-01-06
- Last updated
- 2025-06-17
- Results first posted
- 2025-06-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | 28 days (dose limiting toxicity period) | Adverse events (AEs) that were considered DLTs: * Grade 5 AEs * Grade 4 AEs judged by the Investigator to be treatment-related or judged by the Sponsor as a DLT, regardless of Investigator-attribution (with some exceptions) • Any Grade 4 endocrinopathy. * Grade 3 AEs judged by the Investigator to be treatment-related or by the Sponsor, regardless of Investigator-attribution (with some exceptions) • Any Grade 3 central nervous system event, regardless of duration or reversibility. * Grade 2 pneumonitis necessitating CX-072 discontinuation * Grade 2 ocular toxicity necessitating CX-072 discontinuation |
| Secondary | The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy | 2 years | The primary efficacy endpoint, ORR, was defined as the proportion of subjects with complete response (CR) or partial response (PR) on two consecutive tumor assessments according to RECIST v1.1. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | 28 days (dose limiting toxicity period) | The safety analysis population includes all enrolled subjects who receive at least one dose of study drug. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy | 2 years | Per CX-072-001 Statistical Analysis Plan, efficacy analyses will be limited to subjects who received 10 mg/kg CX-072 as monotherapy during the study. This efficacy subset includes subjects from Parts A, A2 and D. Efficacy summaries will have parts A and A2 combined | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 0.03 mg/kg (Part A and Part A2) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 0.1 mg/kg (Part A and Part A2) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 0.3 mg/kg (Part A and Part A2) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 1 mg/kg (Part A and A2) | 1 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 3 mg/kg (Part A and Part A2) | 1 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 10 mg/kg (Part A and Part A2) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 30 mg/kg (Part A and Part A2) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 0.3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 1 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 1 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 0 | Participants | ||
| The Number of Subjects Experiencing a Dose Limiting Toxicity (DLT) at Various Dose Levels When Given Multiple Doses of CX-072 as a Monotherapy or in Combination With Ipilimumab or Vemurafenib | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 0 | Participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow114
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Study | STARTED | CX-072 0.03 mg/kg (Part A and Part A2) | 2 | |
| Main Study | STARTED | CX-072 0.1 mg/kg (Part A and Part A2) | 2 | |
| Main Study | STARTED | CX-072 0.3 mg/kg (Part A and Part A2) | 8 | |
| Main Study | STARTED | CX-072 1 mg/kg (Part A and Part A2) | 9 | |
| Main Study | STARTED | CX-072 3 mg/kg (Part A and Part A2) | 13 | |
| Main Study | STARTED | CX-072 10 mg/kg (Part A and Part A2) | 16 | |
| Main Study | STARTED | CX-072 30 mg/kg (Part A and Part A2) | 3 | |
| Main Study | STARTED | CX-072 0.3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 6 | |
| Main Study | STARTED | CX-072 1 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 3 | |
| Main Study | STARTED | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 3 |
1 to 10 of 114Source ClinicalTrials.gov
See all 114 participant flowAdverse events7,505
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.03 mg/kg (Part A and Part A2) | 1 | 2 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.1 mg/kg (Part A and Part A2) | 0 | 2 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.3 mg/kg (Part A and Part A2) | 0 | 8 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 1 mg/kg (Part A and Part A2) | 1 | 9 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg (Part A and Part A2) | 4 | 13 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 10 mg/kg (Part A and Part A2) | 4 | 16 | 5 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 30 mg/kg (Part A and Part A2) | 2 | 3 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 0.3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 1 | 6 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 1 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 1 | 3 | 1 |
| other | Anaemia | Blood and lymphatic system disorders | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 0 | 3 | 0 |
1 to 10 of 7,505Source ClinicalTrials.gov
See all 7,505 adverse eventsAdverse event totals57
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CX-072 0.03 mg/kg (Part A and Part A2) | 2 | 2 |
| Total, all-cause mortality | CX-072 0.1 mg/kg (Part A and Part A2) | 2 | 2 |
| Total, all-cause mortality | CX-072 0.3 mg/kg (Part A and Part A2) | 5 | 8 |
| Total, all-cause mortality | CX-072 1 mg/kg (Part A and Part A2) | 4 | 9 |
| Total, all-cause mortality | CX-072 3 mg/kg (Part A and Part A2) | 9 | 13 |
| Total, all-cause mortality | CX-072 10 mg/kg (Part A and Part A2) | 13 | 16 |
| Total, all-cause mortality | CX-072 30 mg/kg (Part A and Part A2) | 3 | 3 |
| Total, all-cause mortality | CX-072 0.3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 5 | 6 |
| Total, all-cause mortality | CX-072 1 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 2 | 3 |
| Total, all-cause mortality | CX-072 3 mg/kg + Ipilimumab 3 mg/kg (Part B1) | 2 | 3 |
1 to 10 of 57Source ClinicalTrials.gov
See all 57 adverse event totalsPapers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03013491
GET https://conductscience.org/api/trials/v1/NCT03013491/flow?page=2